Standout Papers
- Donanemab in Early Alzheimer’s Disease (2021)
- Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease (2020)
- Trial of Solanezumab in Preclinical Alzheimer’s Disease (2023)
- Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease (2022)
- Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease (2025)
Immediate Impact
3 by Nobel laureates 17 from Science/Nature 86 standout
Citing Papers
Medical, surgical, and physical treatments for Parkinson's disease
2024 Standout
Early onset diagnosis in Alzheimer’s disease patients via amyloid-β oligomers-sensing probe in cerebrospinal fluid
2024 Standout
Works of John R. Sims being referenced
Donanemab in Early Alzheimer’s Disease
2021 Standout
The Future of Anti-Amyloid Trials
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| John R. Sims | 1986 | 1107 | 999 | 1253 | 126 | 5.6k | |
| P. O. Yates | 2258 | 827 | 1186 | 1296 | 96 | 5.6k | |
| Vesa Oikonen | 2149 | 770 | 839 | 1020 | 142 | 6.9k | |
| Karen S. SantaCruz | 2361 | 987 | 749 | 1275 | 66 | 5.0k | |
| Raili Raininko | 820 | 717 | 692 | 1006 | 148 | 5.8k | |
| Christine M. Hulette | 2979 | 1028 | 1008 | 2294 | 83 | 5.6k | |
| Dikran S. Horoupian | 1756 | 691 | 2310 | 1173 | 137 | 5.8k | |
| Mark L. Cohen | 1470 | 520 | 890 | 2912 | 175 | 6.1k | |
| Markus J. Riemenschneider | 2991 | 1932 | 1110 | 2712 | 133 | 7.6k | |
| Marilyn J. Cipolla | 1044 | 721 | 808 | 1010 | 151 | 6.0k | |
| John Moossy | 983 | 793 | 1477 | 932 | 151 | 5.7k |
All Works
Loading papers...